Helsinn Healthcare

To see an up-to date selection of historical analyses and insights on Helsinn Healthcare, visit our new, dynamically updated Company Summary report pages for Helsinn Healthcare.

As a Guest User, you will have FREE access to a selection of historical analyses and insights from EvaluatePharma®.

How to access FREE content

  • Search the content using the search box at the top of every page
  • Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
  • Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar

Register for FREE to access even more content including 2007 Product Sales and Rankings.

A small selected sample of reports and related news headlines for Helsinn Healthcare are available below. Free sample reports are also available for other Companies.

To find out how you can access more detailed information on Helsinn Healthcare, or on any other Company covered by EvaluatePharma® Contact Us today.

PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers
 
  Rank Product Therapeutic Category Therapeutic Subcategory Pharmacological Class Phase (Current)
Helsinn Healthcare - Netupitant (R1124) Gastro-Intestinal Anti-emetics Neurokinin-1 antagonist Phase II
  - XL119 Oncology & Immunomodulators Alkaloids Topoisomerase I & II inhibitor Phase II
  - ZP1846 Gastro-Intestinal Other gastro-intestinal agents Glucagon-like peptide 2 (GLP-2) agonist Phase I

DEALS - Selected Company Deals
 
  Rank Deal Date Deal Type Product Status on Deal Date Deal Partner/ Product Source Deal Value
Helsinn Healthcare 1 Nov 2008 In-licensed ZP1846 Phase I Zealand Pharma 178

NEWS - Selected Product News Headlines (as of 11 June 2008)
Helsinn Healthcare SA Announces the FDA’s Approval of ALOXI® (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-Induced Nausea and Vomiting   (Helsinn Healthcare)   25-Aug-2008
FDA Approves ALOXI (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting   (Eisai)   24-Aug-2008
ALOXI® (palonosetron HCl) Injection Available for Prevention of Postoperative Nausea and Vomiting   (Eisai)   09-Jul-2008
Helsinn Healthcare SA Announces the Launch of ALOXI® (palonosetron HCl) Injection for the Prevention of Postoperative Nausea and Vomiting in the USA   (Helsinn Healthcare)   09-Jul-2008
Positive Outcome to Helsinn’s Participation in the 2008 ASCO Annual Meeting Chicago, USA, 30 May – 3 June 2008   (Helsinn Healthcare)   16-Jun-2008
FDA Approves Aloxi® (palonosetron HCl) Injection for Prevention of Postoperative Nausea and Vomiting   (Eisai)   03-Mar-2008
FDA Approves Aloxi® (palonosetron HCl) Injection for Prevention of Postoperative Nausea and Vomiting   (Helsinn Healthcare)   03-Mar-2008
Helsinn Healthcare SA Announces the Launch of Aloxi® (palonosetron) in the UK   (Helsinn Healthcare)   11-Feb-2008

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON
 
  Product Generic Name
Helsinn Healthcare Aloxi palonosetron
  Amolin atenolol
  Aulin nimesulide
  By-Madol tramadol
  By-Mycin doxycycline
  By-Vertin betahistine dichlorhydrate
  Calmax alprazolam
  Calvidin calcium carbonate & vitamin D3
  Casacol methoxyphenamine & guaifenesin
  Danoprox oxaprozin
  Dona glucosamine
  Gelclair sodium hyaluronate & polyvinylpyrrolidone
  Ideos calcium carbonate
  Klean-Prep polyethylene glycol & electrolytes
  Melatonin melatonin
  Netupitant (R1124) netupitant
  Norvedan fentiazac
  Rapolyte sodium & glucose
  Truoxin ciprofloxacin
  XL119 becatecarin
  Zanidip lercanidipine
  ZP1846 -

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts.

Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®.

Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.

Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.